COMMUNIQUÉS West-GlobeNewswire

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
29/09/2026
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on October [...]
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
29/09/2026
Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype that will respond to immune-based intervention SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- [...]
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
29/09/2026
– KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models – – KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of [...]
Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation
29/09/2026
Proprietary intranasal delivery technology being developed initially for GLP-1 receptor agonists LOUGHBOROUGH, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Landmark Medicines Ltd., a UK pharmaceutical development [...]
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
29/09/2026
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE [...]
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
29/09/2026
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of [...]
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
29/09/2026
Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACs BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a [...]
Cascade Prodrug Inc. Appoints Kenneth Mandell, M.D., Ph.D. to Board of Directors
29/09/2026
Ophthalmology industry veteran brings extensive drug development, clinical and entrepreneurial experience as Cascade advances CPD100 for wet age-related macular degeneration EUGENE, Ore., Sept. 29, 2026 (GLOBE NEWSWIRE [...]
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
29/09/2026
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
ABBYY Appoints Paula Sanders to Chief Customer Experience Officer, Providing Customers a Single, End-to-End Experience
29/09/2026
AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) -- ABBYY today announced the appointment of Paula Sanders to Chief Customer Experience Officer (CCXO) to provide customers a consistent, connected experience across every [...]
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
29/09/2026
Trilivy™ is designed to address the challenges of metabolic dysfunction Clients on Trilivy's Reset 5 & 1 Plan who work with a coach lose up to 10 times more weight and 17 times more fat compared to self-directed [...]
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
29/09/2026
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, [...]
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
29/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”) today notes the announcement from Sarborg Limited regarding the filing of new [...]
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
29/09/2026
OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing [...]
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
29/09/2026
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in 2L/3L advanced or metastatic non-squamous NSCLC without actionable genomic [...]
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
29/09/2026
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and [...]
PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026
29/09/2026
Pivotal SkinTE® data in non-healing Wagner Grade 1 diabetic foot ulcers to be presented by Study Chair Robert S. Kirsner, MD, PhD, on October 16 SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) -- PolarityBio® , a late- [...]
Ocugen to Participate in Upcoming October Investor and Industry Conferences
29/09/2026
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of [...]
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
29/09/2026
Company investments from the past five years, together with the forecast for 2026, are projected to reach EUR 500 million by year-end 2026, encompassing all expenditure on sustainability-related projects and health [...]

Pages